Efficacy
DISEASE, BEST
The results of this study have met the statistical hypothesis (PFS = 15mons). As of October 26, 2022, the median follow-up time was 26.9 (range, 15.0-38.9) months. Median PFS and OS were 15.1 (95%CI: 12.6–17.6) and 30.0 (95%CI: 25.5–34.5) months, respectively (Fig. 
Efficacy of the combination of anlotinib + icotinib. Kaplan-Meier curves of PFS and OS in the ITT population 
Best percentage changes from baseline in target lesion size in the efficacy analysis set. CR, complete response; PR, partial response; SD, stable disease; PD, disease progression
Treatment response and duration of response